What’s the current market cap for Ventas stock?

Ventas (VTR) has a market cap of $42bn as of June 25, 2026.

What is the P/E ratio for Ventas stock?

The price to earnings (P/E) ratio for Ventas (VTR) stock is 158.17 as of June 25, 2026.

Does Ventas stock pay dividends?

Yes, the Ventas (VTR) stock pays dividends to shareholders. As of June 25, 2026, the dividend rate is $1.96 and the yield is 2.4%. Ventas has a payout ratio of 342.22% on a trailing twelve-month basis.

When is the next Ventas dividend payment date?

The next Ventas (VTR) dividend payment is scheduled for July 16, 2026.

What is the beta indicator for Ventas?

Ventas (VTR) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Ventas stock | $VTR Share Price

About Ventas

Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.

Ticker

$VTR

Sector

Real Estate

Primary listing

NYSE

Employees

542

Headquarters

Chicago, United States

Website

www.ventasreit.com

Ventas Metrics

BasicAdvanced

$42bn

158.17

$0.55

0.76

$1.96

2.40%

What the Analysts think about Ventas

Analyst ratings (Buy, Hold, Sell) for Ventas stock.

Bulls say / Bears say

Ventas’ Senior Housing Operating Portfolio delivered over 15% same-store NOI growth in Q1 2026, driven by 5% RevPOR growth and a 370 bp U.S. occupancy increase, prompting management to raise its 2026 SHOP NOI guidance to roughly 16%. (MarketBeat)

The company strengthened its balance sheet in Q1, cutting net debt to further adjusted EBITDA to 5.0× from 5.2× in Q4 2025 and ending the quarter with $5.5 billion of liquidity to support accretive investments and buffer against rate volatility. (Investing.com)

Ventas’ Outpatient Medical & Research portfolio grew rental income by 4% year-over-year to $230.1 million, while its triple-net segment achieved 1.6% same-store cash NOI growth in Q1, underpinning diversified revenue streams beyond senior housing. (Yahoo Finance) (MarketBeat)

Some of Ventas’ newly acquired Revel portfolio properties remain in lease-up at mid-70% occupancy, delaying stabilization and deferring expected cash flows against its SHOP targets. (Investing.com)

Q1 operating expenses rose 5.8% year-over-year due to winter storms and higher volume pressures, and higher forward interest rate assumptions are expected to shave approximately $0.01 of FFO per share, highlighting margin sensitivity to macro headwinds. (MarketBeat)

Management noted intensifying competition for senior housing acquisitions and cap-rate compression, which could erode yield accretion on its planned $3 billion of 2026 investment activity and pressure future returns. (Yahoo Finance)

Data summarised monthly by Lightyear AI. Last updated on 19 Jun 2026.

Ventas Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Ventas Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Ventas News

AllArticlesVideos

Ventas Names Andrew L. Wattula EVP Outpatient Medical & Research

Business Wire·2 days ago

Top 3 Real Estate Stocks Which Could Rescue Your Portfolio In June

Benzinga·2 weeks ago

Ventas Issues Business Update and Will Participate in Investor Meetings at Nareit's REITweek 2026 Investor Conference

Business Wire·3 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.